Tiziana Life Sciences PLC ADR (TLSA)

1.060
-0.100(-8.62%)
After Hours
1.060
0.000(0.00%)
- Real-time Data
  • Volume:
    214,295
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.055 - 1.220

TLSA Overview

Prev. Close
1.16
Day's Range
1.055-1.22
Revenue
-
Open
1.14
52 wk Range
1.055-5.29
EPS
-0.23
Volume
214,295
Market Cap
75.36M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
146,487
P/E Ratio
-
Beta
-
1-Year Change
-54.31%
Shares Outstanding
97,306,145
Next Earnings Date
-
What is your sentiment on Tiziana Life Sciences PLC ADR?
or
Market is currently closed. Voting is open during market hours.

Tiziana Life Sciences PLC ADR Company Profile

Employees
11

Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • TLSA (P) 0.00000000 1.66000000
    0
    • Elon Musk pump/dumping Bitcoin and Dogcoin so TSLA getting PUNISHED.....shorts now love crazy/sick Elon Musk....
      0
      • Tiziana Life Sci PLC - FDA Allows Foralumab Treatment for a SPMS Patient 30th March 2021,
        0
        • 💎👋🏻
          0
          • Earnings report on 2/1 and avg analyst rating is $9.50 this yr
            0
            • Any idea what is going on with TLSA?
              0
              • One of my worst investmenst bought at  4.34
                2
                • Last couple of days to hoover these up before the split!!!
                  0
                  • can you see any idea to buy this?
                    1
                    • wait, this is not TSLA
                      0
                      • GUHHH
                        0
                      • that's why the calls for 500 where so cheap! too late I'm loaded lol
                        0
                    • This company is another player in the rush to offer a CoronaVirus Vaccine. Winners will be those that produce a viable vaccine first. TLSA is one of three players poised for huge growth and stock worth ramping to near prior stock highs in the companies winning the race. The other two are AIM and VXRT. These are major stock plays to safety in these bear market times and major profiting in the mix.
                      0
                      • their covid anitbody is the world's only fully human cd3 antibody but they have other world leading drugs in their portfolio so they are not a Covid Company
                        0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.